Browse All

Current Filters

CLEAR FILTER x

TITLE

Ketogenic Diet in Glioblastoma: A Systematic Review and Meta-analysis

Author:Neutel, Dean   Thomas, Steven   Mohammed, Nasser   

Session Name:P7: Neuro-oncology: Clinical Trials and Case Reports 1  

Topic:Neuro-oncology  

Program Number:P7.004  

Author Institution:Virginia Tech Carilion, Roanoke, VA  Virginia Tech Carilion, VA  Carilion Clinic, VA  

Ketogenic Diet May Reduce Seizure Burden in Rett Patients with FOXG1 Mutation

Author:Pichon, Pilar   Engelhart, Darcy   Mounts, Kira   Shah, Naman   Kalawi, Adam   Steenari, Maija   

Session Name:P2: Child Neurology and Developmental Neurology: Epilepsy 1  

Topic:Child Neurology and Developmental Neurology  

Program Number:P2.006  

Author Institution:Children's Hospital of Orange County, Loma Linda University Children's Hospital, and UCI, CA  Children's Hospital of Orange County and UCI, CA  Children's Hospital of Orange County, CA  Children's Hospital of Orange County, Orange, CA  

Key Predictors of 90-Day Functional Outcome for Patients with Large Infarct Core Undergoing Endovascular Therapy in Real-world Practice

Author:Cherukuri, Harshita   Waworuntu, Demi   Marioni, Sergio   Mallavarapu, Monica   Iyyangar, Ananya   Sheth, Sunil   Jeevarajan, Jerome   

Session Name:S31: Stroke Risk Factors, Outcomes, and Prevention  

Topic:Cerebrovascular Disease and Interventional Neurology  

Program Number:S31.006  

Author Institution:The University of Texas Health Houston, McGovern Medical School, Houston, TX, Hyderabad, India  The University of Texas Health Houston, McGovern Medical School, Houston, TX, Houston, TX  

KHN702, a Novel Selective hNav1.8 Inhibitor for Pain Therapy

Author:Liu, Ting   Huang, Hong   Mu, Ke   Yu, yongguo   Cai, Zuhuan   Bai, Yu   Ke, Xiao   

Session Name:S38: Pain  

Topic:Pain  

Program Number:S38.002  

Author Institution:Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu, China, People's Republic of  Chengdu Kanghong Pharmaceutical Group Co., Ltd, Chengdu Sichuan , China, People's Republic of  Chengdu Kanghong Pharmaceutical Group Co., Ltd, sichuan chengdu, China, People's Republic of  

KITE-363: An Autologous Anti-CD19/CD20 CAR-T Product for the Treatment of Neuroinflammatory Autoimmune Diseases

Author:Lowe, Christine   Kim, Brian   Flores, Francisco   Margaitis, Jeremy   Calo, Alessandro   Konecny, Anna   Jaghatspanyan, Eva   Yoder, Sean   Ertel, Kenneth   Filosto, Simone   Murakami, Jodi   Barrett, David   

Session Name:P10: Multiple Sclerosis: Clinical Science 2  

Topic:Multiple Sclerosis  

Program Number:P10.004  

Author Institution:Kite Pharma, Santa Monica, CA  Kite Pharma, CA